Minghui Pharmaceutical is preparing to launch a first-in-human clinical trial of MHB009C, an investigational antibody-drug conjugate (ADC) targeting advanced solid tumors. Hosted by the Fudan University Shanghai Cancer Center, the Phase I/II study (NCT07326488) will evaluate the safety, tolerability, and preliminary efficacy of MHB009C in 200 patients with treatment-refractory malignancies.
The trial represents an early-stage exploration of a novel therapeutic approach targeting B7-H4, an immune checkpoint molecule frequently overexpressed in solid tumors. By combining an antibody targeting B7-H4 with a cytotoxic payload, MHB009C aims to selectively deliver therapeutic agents to malignant cells while potentially minimizing damage to healthy tissue.
In terms of study design, patients will be enrolled across two primary phases: an initial dose-escalation stage to determine safety and maximum tolerated dose, followed by a dose-expansion cohort to assess preliminary efficacy in specific tumor types. Key design elements include: an open-label, multicenter protocol, with seven planned dose-escalation cohorts. Enrollment will focus on patients with histologically confirmed advanced solid tumors. Primary endpoints focus on dose-limiting toxicity and objective response rates
Research Context
B7-H4 (VTCN1/B7x/B7S1) has emerged as a promising immuno-oncology target, particularly for solid tumors with limited response to established checkpoint inhibitors. B7-H4 is an immune checkpoint molecule overexpressed in various cancers, where it contributes to immune evasion and correlates with poor prognosis.
The B7-H4 development field has quickly become crowded, with ADCs targeting solid tumors to the fore and activity centered in breast and gynecologic cancers (ovarian and endometrial in particular). The most advanced program is AstraZeneca’s puxitatug samrotecan (AZD8205), now in phase 3 in endometrial cancer, while Pfizer (via Seagen) is advancing felmetatug vedotin (SGN-B7H4V) in phase 1/2 across advanced solid tumors including breast and gynecologic malignancies. Behind these leaders, Mersana Therapeutics is developing emiltatug ledadotin (XMT-1660/Emi-Le) in phase 1, and GlaxoSmithKline is pushing GSK5733584 (HS-20089), an ADC licensed from Hansoh, in phase 1/2—highlighting both the depth of multinational interest and the importance of China-originated assets in the category.
Beyond these front-runners, the active pipeline includes Shanghai Hansoh Biomedical’s LNCB74 (phase 1) and the earlier monoclonal antibody effort FPA150 (Five Prime, now under Amgen; phase 1 completed with limited recent disclosure post-acquisition). Modality diversification is also beginning to show through, with bispecific concepts entering preclinical/early clinical development and exploratory cancer vaccine work reported in academic settings (e.g., glioma-focused programs). Differentiation will hinge on head-to-head tolerability versus other ADCs, clearer biomarker-defined patient selection (B7-H4-high disease), and evidence that any given construct can sustain responses or combine cleanly with existing IO and cytotoxic backbones.